SEARCH

SEARCH BY CITATION

References

  • Bae E. J., Lee H. J., Rockenstein E., Ho D. H., Park E. B., Yang N. Y., Desplats P., Masliah E. and Lee S. J. (2012) Antibody-Aided Clearance of Extracellular alpha-Synuclein Prevents Cell-to-Cell Aggregate Transmission. J. Neurosci. 32, 1345413469.
  • Bartels T., Choi J. G. and Selkoe D. J. (2011) alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477, 107110.
  • Beal M. F. (2010) Parkinson's disease: a model dilemma. Nature 466, S8S10.
  • Burre J., Sharma M., Tsetsenis T., Buchman V., Etherton M. R. and Sudhof T. C. (2010) Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329, 16631667.
  • Campbell B. C., Li Q. X., Culvenor J. G., Jakala P., Cappai R., Beyreuther K., Masters C. L. and McLean C. A. (2000) Accumulation of insoluble alpha-synuclein in dementia with Lewy bodies. Neurobiol. Dis. 7, 192200.
  • Cappai R., Leck S. L., Tew D. J. et al. (2005) Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J. 19, 13771379.
  • Cole N. B., Murphy D. D., Lebowitz J., Di Noto L., Levine R. L. and Nussbaum R. L. (2005) Metal-catalyzed oxidation of alpha-synuclein: helping to define the relationship between oligomers, protofibrils, and filaments. J. Biol. Chem. 280, 96789690.
  • Colla E., Jensen P. H., Pletnikova O., Troncoso J. C., Glabe C. and Lee M. K. (2012a) Accumulation of toxic alpha-synuclein oligomer within endoplasmic reticulum occurs in alpha-synucleinopathy in vivo. J. Neurosci. 32, 33013305.
  • Colla E., Coune P., Liu Y., Pletnikova O., Troncoso J. C., Iwatsubo T., Schneider B. L. and Lee M. K.. (2012b). “Endoplasmic reticulum stress is important for the manifestations of alpha-synucleinopathy in vivo.” J. Neurosci. 32, 33063320.
  • Conway K. A., Lee S. J., Rochet J. C., Ding T. T., Williamson R. E. and Lansbury P. T., Jr (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 97, 571576.
  • Cox B. and Emili A.. (2006). Tissue subcellular fractionation and protein extraction for use in mass-spectrometry-based proteomics. Nat. Protoc. 4, 18721878
  • Danzer K. M., Haasen D., Karow A. R., Moussaud S., Habeck M., Giese A., Kretzschmar H., Hengerer B. and Kostka M. (2007) Different species of alpha-synuclein oligomers induce calcium influx and seeding. J. Neurosci. 27, 92209232.
  • Del Tredici K. and Braak H. (2012) Spinal cord lesions in sporadic Parkinson's disease. Acta Neuropathol. 124, 643664.
  • Diogenes M. J., Dias R. B., Rombo D. M. et al. (2012) Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J. Neurosci. 32, 1175011762.
  • Ehrnhoefer D. E., Bieschke J., Boeddrich A., Herbst M., Masino L., Lurz R., Engemann S., Pastore A. and Wanker E. E. (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol. 15, 558566.
  • Emadi S., Barkhordarian H., Wang M. S., Schulz P. and Sierks M. R. (2007) Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J. Mol. Biol. 368, 11321144.
  • Englund H., Sehlin D., Johansson A. S., Nilsson L. N., Gellerfors P., Paulie S., Lannfelt L. and Pettersson F. E. (2007) Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J. Neurochem. 103, 334345.
  • Fauvet B., Mbefo M. K., Fares M. B. et al. (2012). Alpha-synuclein in the central nervous system and from erythrocytes, mammalian cells and E. coli exists predominantly as a disordered monomer. J. Biol. Chem. 19, 1534515364.
  • Freichel C., Neumann M., Ballard T. et al. (2007) Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice. Neurobiol. Aging 28, 14211435.
  • Harding A. J. and Halliday G. M. (2001) Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol. 102, 355363.
  • Kahle P. J., Neumann M., Ozmen L. et al. (2000) Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J. Neurosci. 20, 63656373.
  • Kahle P. J., Neumann M., Ozmen L. et al. (2001) Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am. J. Pathol. 159, 22152225.
  • Kayed R., Canto I., Breydo L. et al. (2010) Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Abeta oligomers. Mol. Neurodegener. 5, 57.
  • Klucken J., Ingelsson M., Shin Y., Irizarry M. C., Hedley-Whyte E. T., Frosch M., Growdon J., McLean P. and Hyman B. T. (2006) Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies. Acta Neuropathol. 111, 101108.
  • Konno T., Morii T., Hirata A., Sato S., Oiki S. and Ikura K. (2005) Covalent blocking of fibril formation and aggregation of intracellular amyloidgenic proteins by transglutaminase-catalyzed intramolecular cross-linking. Biochemistry 44, 20722079.
  • Leverenz J. B., Umar I., Wang Q. et al. (2007) Proteomic identification of novel proteins in cortical lewy bodies. Brain Pathol. 17, 139145.
  • Martin Z. S., Neugebauer V., Dineley K. T., Kayed R., Zhang W., Reese L. C. and Taglialatela G. (2012) alpha-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases. J. Neurochem. 120, 440452.
  • Masliah E., Rockenstein E., Mante M. et al. (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE 6, e19338.
  • Mollenhauer B., Cullen V., Kahn I. et al. (2008) Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol. 213, 315325.
  • Nasstrom T., Wahlberg T., Karlsson M., Nikolajeff F., Lannfelt L., Ingelsson M. and Bergstrom J. (2009) The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links alpha-synuclein causing rapid formation of stable oligomers. Biochem. Biophys. Res. Commun. 378, 872876.
  • Nasstrom T., Fagerqvist T., Barbu M., Karlsson M., Nikolajeff F., Kasrayan A., Ekberg M., Lannfelt L., Ingelsson M. and Bergstrom J. (2011) The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of alpha-synuclein oligomers with distinct biochemical, morphological, and functional properties. Free Radic. Biol. Med. 50, 428437.
  • Nemani V. M., Lu W., Berge V., Nakamura K., Onoa B., Lee M. K., Chaudhry F. A., Nicoll R. A. and Edwards R. H. (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65, 6679.
  • Neri D., Montigiani S. and Kirkham P. M. (1996) Biophysical methods for the determination of antibody-antigen affinities. Trends Biotechnol. 14, 465470.
  • Neumann M., Kahle P. J., Giasson B. I. et al. (2002) Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J. Clin. Invest. 110, 14291439.
  • Oinas M., Paetau A., Myllykangas L., Notkola I. L., Kalimo H. and Polvikoski T. (2010) alpha-Synuclein pathology in the spinal cord autonomic nuclei associates with alpha-synuclein pathology in the brain: a population-based Vantaa 85+ study. Acta Neuropathol. 119, 715722.
  • Paleologou K. E., Kragh C. L., Mann D. M., Salem S. A., Al-Shami R., Allsop D., Hassan A. H., Jensen P. H. and El-Agnaf O. M. (2009) Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 132, 10931101.
  • Parnetti L., Chiasserini D., Bellomo G. et al. (2011) Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias. Mov. Disord. 26, 14281435.
  • Roy S. (2009) The paradoxical cell biology of alpha-Synucle. Results Probl. Cell Differ. 48, 159172.
  • Schell H., Hasegawa T., Neumann M. and Kahle P. J. (2009) Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice. Neuroscience 160, 796804.
  • Sharon R., Bar-Joseph I., Frosch M. P., Walsh D. M., Hamilton J. A. and Selkoe D. J. (2003) The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37, 583595.
  • Souza J. M., Giasson B. I., Chen Q., Lee V. M. and Ischiropoulos H. (2000) Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 275, 1834418349.
  • de StGroth S. F. and Scheidegger D. (1980) Production of monoclonal antibodies: strategy and tactics. J. Immunol. Methods 35, 121.
  • Tokuda T., Salem S. A., Allsop D., Mizuno T., Nakagawa M., Qureshi M. M., Locascio J. J., Schlossmacher M. G. and El-Agnaf O. M. (2006) Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349, 162166.
  • Tokuda T., Qureshi M. M., Ardah M. T., Varghese S., Shehab S. A., Kasai T., Ishigami N., Tamaoka A., Nakagawa M. and El-Agnaf O. M.. (2010). Detection of elevated levels of {alpha}-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 20, 17661772.
  • Uversky V. N., Li J. and Fink A. L. (2001) Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem. 276, 1073710744.
  • Volles M. J., Lee S. J., Rochet J. C., Shtilerman M. D., Ding T. T., Kessler J. C. and Lansbury P. T., Jr (2001) Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40, 78127819.
  • Wakabayashi K., Mori F., Tanji K., Orimo S. and Takahashi H. (2010) Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain. Acta Neuropathol. 120, 112.
  • Wilms H., Rosenstiel P., Romero-Ramos M. et al. (2009) Suppression of MAP kinases inhibits microglial activation and attenuates neuronal cell death induced by alpha-synuclein protofibrils. Int. J. Immunopathol. Pharmacol. 22, 897909.
  • Winner B., Jappelli R., Maji S. K. et al. (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. USA 108, 41944199.
  • Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E. R. and Mizuno Y. (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl Acad. Sci. USA 93, 26962701.
  • Zhu M., Rajamani S., Kaylor J., Han S., Zhou F. and Fink A. L. (2004) The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. J. Biol. Chem. 279, 2684626857.